Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients...
United Kingdom Alexandra Balcom James Porter Piper Sandler Exchange Commission Prnewswire Nuvalent Inc
Source: prnewswire.com